Amylyx director Justin Klee proposes $2.95M share sale

The notice lists 128,562,904 common shares outstanding, providing share-count context for the proposed sale.

Available on EDGAR 11/09/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. director and officer Justin Klee reported a proposed sale of 100,000 common shares, with an aggregate market value of $2,950,000 and an approximate sale date of November 9, 2026.

The shares are identified as “Founders Shares” acquired from the issuer on January 13, 2014. The notice lists May 11, 2026 as the plan adoption or instruction date for a Rule 10b5-1 plan. Klee also reported selling 30,464 common shares on September 10, 2026, for gross proceeds of $980,263.27.

Key Figures

Common shares proposed for sale: 100,000 shares Aggregate market value: $2,950,000 Common shares outstanding: 128,562,904 shares +3 more

6 metrics

Common shares proposed for sale 100,000 shares Approximate sale date November 9, 2026

Aggregate market value $2,950,000 Proposed sale of common shares

Common shares outstanding 128,562,904 shares Number listed in the notice

Common shares sold 30,464 shares Sale on September 10, 2026

Gross proceeds $980,263.27 Sale on September 10, 2026

Rule 10b5-1 plan adoption or instruction date May 11, 2026 Date listed for reliance on a Rule 10b5-1 plan

Key Terms

Rule 10b5-1, Founders Shares, Aggregate Market Value, Gross Proceeds

4 terms

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Founders Shares financial

"Nature of Acquisition Transaction: Founders Shares"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

Aggregate Market Value financial

"Aggregate Market Value | 2950000.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Amount of Securities Sold | Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AMLX shares did Justin Klee plan to sell?

Justin Klee reported a proposed sale of 100,000 common shares, with an aggregate market value of $2,950,000 and an approximate sale date of November 9, 2026. The notice lists May 11, 2026 as the plan adoption or instruction date for a Rule 10b5-1 plan.

How many AMLX shares did Justin Klee sell recently?

Klee reported selling 30,464 common shares on September 10, 2026, for gross proceeds of $980,263.27.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001898314
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AMYLYX PHARMACEUTICALS, INC.
SEC File Number	001-41199
Address of Issuer	55 Cambridge Parkway, Suite 6W CAMBRIDGE MASSACHUSETTS 02142
Phone	(617)-682-0917
Name of Person for Whose Account the Securities are To Be Sold	JUSTIN KLEE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	2950000.00	128562904	11/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/13/2014	Founders Shares	Issuer			100000	01/13/2014	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JUSTIN KLEE 55 Cambridge Parkway, Suite 6W CAMBRIDGE MA 02142	Common	09/10/2026	30464	980263.27

144: Remarks and Signature

Remarks
Date of Notice	11/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Justin Klee
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)